Retrospective Review on Breast Cancer Patients to Assess Molecular Classification

Breast cancer is a heterogeneous group of tumors that differ in morphology, clinical course and sensitivity to treatment. The classification of breast tumors published by WHO includes numerous histological forms. The majority of breast cancer is represented by invasive protocol cancer, without additional clarifications and is about 50 - 80%. Based on the immuno-histochemical study of the expression of breast carcinoma of the chest receptors for estrogen and progesterone (ER, PR) and receptor of the epidermal growth factor of the second type (HЕR2/neu, ErbB2), BC is classified into 4 molecular subtypes. These subtypes differ among themselves according to the prognosis of the course and the response to medical therapy. In general, the luminal, HER2 + and triple negative (TH) molecular subtypes of the breast cancer are distinguished. According to modern concepts, patients with hormone-sensitive tumors, positive for estrogen receptor (ER) and / or progesterone (PgR) receptors, are clearly distinguished by their biological characteristics. These tumors are characterized by the presence of Her-2 / neu hyper expression, and patients with so-called triple negative tumors that are negative in both ER and / or PgR content and Her-2 / neu content. Current retrospective review aims to assess the molecular classification of breast cancer